BrainStorm Cell Therapeutics Inc. Receives US Notice Of Allowance For Its Key Stem Cell Technology Patent

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

NEW YORK & PETACH TIKVAH, Israel--(BUSINESS WIRE)--BrainStorm Cell Therapeutics (OTC.QB: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, today announced that it has received a Notice of Allowance from the U.S. Patent Office for its “Mesenchymal Stem Cells for the Treatment of CNS Diseases” (serial number 12/994,761) patent application.

Help employers find you! Check out all the jobs and post your resume.
MORE ON THIS TOPIC